57991-54-5Relevant articles and documents
2-substituted parazoleamino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof
-
Paragraph 0123-0126, (2019/04/10)
The invention relates to a series of new compounds as a JAK inhibitor, as well as compositions and applications thereof, and particularly provides a series of compounds (I) that have a strong JAK inhibiting activity, or stereisomers, geometrical isomers, tautomers, pharmaceutically acceptable salts, prodrugs, metabolites, isotope derivatives, and solvates, as well as medicine compositions comprising such compounds. The invention also discloses applications of the compounds or the medicine compositions in preparation of a medicine, which is used for treatment of autoimmune diseases or cancer.
Quantitative structure-activity relationships of 2,4-diamino-5-(2-X- benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase
Selassie, Cynthia Dias,Gan, Wei-Xi,Kallander, Lara S.,Klein, Teri E.
, p. 4261 - 4272 (2007/10/03)
Quantitative structure-activity relationships (QSAR) have been formulated for a set of 15 2,4-diamino-5-(2-X-benzyl)pyrimidines versus dihydrofolate reductase from Lactobacillus casei and chicken liver. QSARs were also developed for comprehensive data sets containing mono-, di-, and trisubstituted benzyl derivatives. Particular emphasis was placed on the role played by ortho substituents in the overall binding process and subsequent inhibition of the catalytic process in both the prokaryotic and eucaryotic DHFRs. Comparisons between the two QSARs reveal subtle differences at specific positions which can be optimized to design more selective antibacterial agents.